← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Kiniksa Pharmaceuticals, Ltd. (KNSA) 10-Year Financial Performance & Capital Metrics

KNSA •
HealthcareBiotechnologyImmunology and Inflammation Therapies
AboutKiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.Show more
  • Revenue $678M +60.1%
  • EBITDA $79M +279.7%
  • Net Income $119M +374.9%
  • EPS (Diluted) 0.75 +225.0%
  • Gross Margin -
  • EBITDA Margin 11.65% +212.2%
  • Operating Margin 11.4% +205.7%
  • Net Margin 17.52% +271.7%
  • ROE 23.6% +339.7%
  • ROIC 17.13% +252.2%
  • Debt/Equity 0.02 -25.6%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free

✗Weaknesses

  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Shares diluted 10.6% in last year

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y45.45%
TTM60.09%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-13.49%
TTM374.88%

EPS CAGR

10Y-
5Y-
3Y-33.93%
TTM223.97%

ROCE

10Y Avg-45.46%
5Y Avg-12.03%
3Y Avg-0.48%
Latest13.98%

Peer Comparison

Immunology and Inflammation Therapies
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
TGTXTG Therapeutics, Inc.4.75B30.09200.6040.8%13.31%21.87%1.14
APLSApellis Pharmaceuticals, Inc.2.65B20.96116.44-11.77%3.25%7.48%1.71%0.30
ARGXargenx SE47.46B766.9260.0178.6%23.34%15.14%0.01
KNSAKiniksa Pharmaceuticals, Ltd.3.39B44.4959.3260.09%17.52%20.92%0.75%0.02
AUPHAurinia Pharmaceuticals Inc.1.88B14.176.8520.38%101.47%49.4%7.22%0.13
GLPGGalapagos N.V.2.22B33.665.88303.48%28.85%9.92%0.00
AKTXAkari Therapeutics, Plc12.56B0.24-0.00-69.35%0.15
RAPTRAPT Therapeutics, Inc.7.65B57.98-2.27-69.51%0.02

Compare KNSA vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs ARGX

Compare head-to-head with argenx SE

vs CANF

Compare head-to-head with Can-Fite BioPharma Ltd.

Compare Top 5

vs ARGX, CANF, AKTX, ABVX

Profit & Loss

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Sales/Revenue+0000038.54M220.18M270.26M423.24M677.56M
Revenue Growth %------471.24%22.74%56.61%60.09%
Cost of Goods Sold+22K28K286K3.28M3.81M9.1M22.89M56.52M60.91M0
COGS % of Revenue-----23.61%10.4%20.91%14.39%-
Gross Profit+-22K-28K-286K-3.28M-3.81M29.44M197.28M213.74M362.33M0
Gross Margin %-----76.39%89.6%79.09%85.61%-
Gross Profit Growth %--27.27%-921.43%-1046.5%-16.04%873.82%570.03%8.34%69.52%-100%
Operating Expenses+24M65.4M108.16M166.68M153.56M186.08M187.51M238.93M407.94M600.34M
OpEx % of Revenue-----482.77%85.16%88.41%96.39%88.6%
Selling, General & Admin6.56M9.04M21.56M33.75M43.92M85.95M97.95M129.43M168.01M196.27M
SG&A % of Revenue-----222.99%44.49%47.89%39.7%28.97%
Research & Development17.44M56.36M86.6M132.93M109.64M99.3M65.49M76.1M111.62M96.85M
R&D % of Revenue-----257.62%29.74%28.16%26.37%14.29%
Other Operating Expenses00000835K24.07M33.41M128.31M307.22M
Operating Income+-24M-65.4M-108.16M-169.96M-157.36M-156.64M9.77M-25.2M-45.62M77.22M
Operating Margin %------406.38%4.44%-9.32%-10.78%11.4%
Operating Income Growth %--172.48%-65.38%-57.14%7.41%0.46%106.24%-357.81%-81.04%269.28%
EBITDA+-23.98M-65.37M-107.87M-166.68M-153.56M-154.28M12.18M-22.86M-43.92M78.92M
EBITDA Margin %------400.27%5.53%-8.46%-10.38%11.65%
EBITDA Growth %--172.61%-65.02%-54.52%7.87%-0.47%107.89%-287.72%-92.17%279.68%
D&A (Non-Cash Add-back)22K28K286K3.28M3.81M2.35M2.4M2.34M1.7M1.7M
EBIT-24M-65.4M-108.16M-163.91M-156.23M-156.64M9.77M-25.2M-45.62M88.87M
Net Interest Income+0006.05M1.13M97K1.25M8.54M9.46M0
Interest Income65K529K4.72M6.05M1.13M97K1.25M8.54M9.46M0
Interest Expense0000000000
Other Income/Expense65K529K4.72M6.05M1.13M97K1.25M8.54M9.46M0
Pretax Income+-23.94M-64.87M-103.44M-163.91M-156.23M-156.54M11.03M-16.65M-36.15M88.87M
Pretax Margin %------406.13%5.01%-6.16%-8.54%13.12%
Income Tax+36K2K-214K-2.05M5.15M1.39M-172.34M-30.74M7.04M-29.86M
Effective Tax Rate %100.15%100%99.79%98.75%103.3%100.88%1663.01%-84.58%119.48%133.6%
Net Income+-23.97M-64.87M-103.23M-161.87M-161.38M-157.92M183.36M14.08M-43.19M118.73M
Net Margin %------409.72%83.28%5.21%-10.21%17.52%
Net Income Growth %--170.61%-59.12%-56.81%0.3%2.14%216.11%-92.32%-406.68%374.88%
Net Income (Continuing)-23.97M-64.87M-103.23M-161.87M-161.38M-157.92M183.36M14.08M-43.19M118.73M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-0.74-2.00-3.49-2.99-2.61-2.302.600.20-0.600.75
EPS Growth %--170.27%-74.5%14.33%12.71%11.88%213.04%-92.31%-400%225%
EPS (Basic)-0.74-2.00-3.49-2.99-2.61-2.302.640.20-0.600.80
Diluted Shares Outstanding32.47M32.47M29.55M54.05M61.84M68.58M70.42M71.92M71.42M78.98M
Basic Shares Outstanding32.47M32.47M29.55M54.05M61.84M68.58M69.38M70.06M71.42M74.2M
Dividend Payout Ratio----------

Balance Sheet

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Current Assets+56.33M47.1M313.75M241.63M333.25M196.45M243.06M276.3M331.8M527.18M
Cash & Short-Term Investments55.97M45.55M307.3M233.38M323.48M182.2M190.61M206.37M243.63M414.07M
Cash Only55.97M45.55M307.3M46.93M114.04M122.47M122.72M107.95M183.58M165.6M
Short-Term Investments000186.45M209.44M59.73M67.89M98.42M60.05M248.48M
Accounts Receivable000003.98M20.32M21.27M41.72M15.59M
Days Sales Outstanding-----37.7433.6828.7235.988.4
Inventory000003.67M21.6M31.12M26.36M54.9M
Days Inventory Outstanding-----147.4344.34200.97157.98-
Other Current Assets105K105K6.45M0210K010.54M17.54M20.08M42.61M
Total Non-Current Assets+133K388K8.21M12.91M16.21M36.35M216.61M250.03M248.75M236.46M
Property, Plant & Equipment84K125K6.36M8.32M10.62M8.38M7.04M12.66M11.04M11.75M
Fixed Asset Turnover-----4.60x31.26x21.34x38.34x57.67x
Goodwill0000000000
Intangible Assets0000019.25M18.25M17.25M16.25M15.25M
Long-Term Investments00210K0000000
Other Non-Current Assets8K25K643K210K5.59M8.72M5.82M827K10.31M11.31M
Total Assets+56.47M47.49M321.96M254.53M349.46M232.8M459.67M526.32M580.55M763.63M
Asset Turnover-----0.17x0.48x0.51x0.73x0.89x
Asset Growth %--15.89%577.94%-20.94%37.3%-33.38%97.45%14.5%10.3%31.54%
Total Current Liabilities+2.3M17.43M42.55M27.83M31.85M44.82M47.07M63.67M100.62M139.18M
Accounts Payable212K1.22M10.92M5.69M503K1.87M7.9M8.25M2.04M2.03M
Days Payables Outstanding3.52K15.88K13.93K633.7148.2574.93125.9353.2512.22-
Short-Term Debt0000000002.99M
Deferred Revenue (Current)0000000307K031.81M
Other Current Liabilities1.1M14.64M25.96M7.11M7.74M1.54M16.97M36.91M96.59M102.36M
Current Ratio24.47x2.70x7.37x8.68x10.46x4.38x5.16x4.34x3.30x3.79x
Quick Ratio24.47x2.70x7.37x8.68x10.46x4.30x4.71x3.85x3.04x3.39x
Cash Conversion Cycle-----110.22252.09176.44181.75-
Total Non-Current Liabilities+79.9M119.77M144K1.28M5.68M2.94M16.46M23.82M41.5M56.84M
Long-Term Debt0000000006.51M
Capital Lease Obligations000955K4.88M2.67M2.62M10.01M7.86M0
Deferred Tax Liabilities001.22M0000000
Other Non-Current Liabilities79.9M119.77M144K326K805K270K1.84M1.86M1.82M50.33M
Total Liabilities82.2M137.2M42.7M29.11M37.53M47.76M63.52M87.48M142.12M196.03M
Total Debt+0002.65M6.99M6.05M5.92M12.26M9.86M9.5M
Net Debt-55.97M-45.55M-307.3M-44.28M-107.05M-116.42M-116.8M-95.7M-173.73M-156.1M
Debt / Equity---0.01x0.02x0.03x0.01x0.03x0.02x0.02x
Debt / EBITDA------0.49x--0.12x
Net Debt / EBITDA-------9.59x---1.98x
Interest Coverage----------
Total Equity+-25.73M-89.71M-194.22M225.42M311.94M185.04M396.15M438.84M438.44M567.61M
Equity Growth %--248.62%-116.51%216.06%38.38%-40.68%114.09%10.78%-0.09%29.46%
Book Value per Share-0.79-2.76-6.574.175.042.705.636.106.147.19
Total Shareholders' Equity-25.73M-89.71M-194.22M225.42M311.94M185.04M396.15M438.84M438.44M567.61M
Common Stock1K1K13K15K18K18K19K20K20K21K
Retained Earnings-26.13M-91M-194.22M-356.09M-517.47M-675.4M-492.03M-477.95M-521.14M-462.14M
Treasury Stock0000000000
Accumulated OCI-24K-52K-4K33K-34K-66K44K6K-163K-25K
Minority Interest0000000000

Cash Flow

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from Operations+-21.87M-50.22M-81.01M-158.37M-136.53M-126.3M5.81M13.3M25.69M25.69M
Operating CF Margin %------327.67%2.64%4.92%6.07%3.79%
Operating CF Growth %--129.66%-61.32%-95.49%13.79%7.5%104.6%129.05%93.14%0%
Net Income-23.97M-64.87M-103.23M-161.87M-161.38M-157.92M183.36M14.08M-43.19M-43.19M
Depreciation & Amortization22K28K286K2.07M2.4M2.35M2.4M2.34M1.7M1.7M
Stock-Based Compensation368K897K5.7M15.08M20.88M25.17M25.12M27.15M30.69M30.69M
Deferred Taxes-46K-197K-978K-3.16M4.36M11K-185.5M-33.79M8.13M8.13M
Other Non-Cash Items293K-53K-1.12M6.53M1.52M3.4M2.99M2.17M3.55M-23.27M
Working Capital Changes1.76M13.93M18.33M-17.02M-4.32M689K-22.57M1.35M24.81M51.63M
Change in Receivables00000-3.91M-16.33M-950K-20.46M26.13M
Change in Inventory00000-3.67M-17.92M-9.52M4.76M4.76M
Change in Payables119K1.01M8.82M-4.71M-4.97M1.37M6.03M347K-6.31M-6.31M
Cash from Investing+-3K-69K-239.2M49.21M-23.44M128.63M-8.08M-29.56M37.67M37.67M
Capital Expenditures-3K-69K-5.29M-3.2M-283K-415K-105K-130K-277K-277K
CapEx % of Revenue-----1.08%0.05%0.05%0.07%0.04%
Acquisitions000-52.42M23.16M00025K0
Investments----------
Other Investing00-233.91M52.42M-23.16M-20M91K0025K
Cash from Financing+42.51M39.87M346.74M84.11M227.09M5.88M2.52M1.5M12.27M12.27M
Debt Issued (Net)0000000000
Equity Issued (Net)1000K1000K1000K1000K1000K01000K-1000K-1000K-1000K
Dividends Paid0000000000
Share Repurchases0000000-2.21M-4.98M-7.73M
Other Financing10K0-3.28M1M-1.14M5.88M-901K3.7M17.25M20M
Net Change in Cash20.64M-10.41M26.53M-25.05M67.11M8.22M245K-14.76M75.63M75.63M
Free Cash Flow+-21.87M-50.29M-86.3M-161.57M-136.81M-146.71M5.7M13.17M25.41M25.41M
FCF Margin %------380.64%2.59%4.87%6%3.75%
FCF Growth %--129.94%-71.62%-87.22%15.32%-7.23%103.89%130.99%92.94%0%
FCF per Share-0.67-1.55-2.92-2.99-2.21-2.140.080.180.360.32
FCF Conversion (FCF/Net Income)0.91x0.77x0.78x0.98x0.85x0.80x0.03x0.94x-0.59x0.22x
Interest Paid0000000000
Taxes Paid115K290K383K1.72M482K1.28M10.69M5.61M2M0

Key Ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)----1037.68%-60.06%-63.55%63.1%3.37%-9.85%23.6%
Return on Invested Capital (ROIC)----70.37%-61.15%-85.91%4.21%-6.07%-11.26%17.13%
Gross Margin-----76.39%89.6%79.09%85.61%-
Net Margin------409.72%83.28%5.21%-10.21%17.52%
Debt / Equity---0.01x0.02x0.03x0.01x0.03x0.02x0.02x
FCF Conversion0.91x0.77x0.78x0.98x0.85x0.80x0.03x0.94x-0.59x0.22x
Revenue Growth------471.24%22.74%56.61%60.09%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.